Charles Schwab’s West Pharmaceutical WST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $210M | Buy |
583,984
+29,652
| +5% | +$9.07M | 0.03% | 443 |
|
|
2026
Q1 | $139M | Buy |
554,332
+11,529
| +2% | +$2.87M | 0.02% | 574 |
|
|
2025
Q4 | $149M | Buy |
542,803
+15,639
| +3% | +$4.28M | 0.02% | 530 |
|
|
2025
Q3 | $138M | Buy |
527,164
+24,810
| +5% | +$6.03M | 0.02% | 552 |
|
|
2025
Q2 | $110M | Buy |
502,354
+10,527
| +2% | +$2.25M | 0.02% | 638 |
|
|
2025
Q1 | $110M | Buy |
491,827
+23,707
| +5% | +$6.53M | 0.02% | 611 |
|
|
2024
Q4 | $153M | Buy |
468,120
+19,936
| +4% | +$6.27M | 0.03% | 464 |
|
|
2024
Q3 | $135M | Buy |
448,184
+6,756
| +2% | +$2.07M | 0.03% | 514 |
|
|
2024
Q2 | $145M | Buy |
441,428
+6,464
| +1% | +$2.28M | 0.03% | 479 |
|
|
2024
Q1 | $172M | Buy |
434,964
+12,146
| +3% | +$4.49M | 0.04% | 396 |
|
|
2023
Q4 | $149M | Buy |
422,818
+8,094
| +2% | +$2.86M | 0.04% | 403 |
|
|
2023
Q3 | $156M | Buy |
414,724
+4,069
| +1% | +$1.57M | 0.04% | 351 |
|
|
2023
Q2 | $157M | Buy |
410,655
+5,037
| +1% | +$1.8M | 0.04% | 356 |
|
|
2023
Q1 | $141M | Sell |
405,618
-42,645
| -10% | -$12.5M | 0.04% | 381 |
|
|
2022
Q4 | $105M | Buy |
448,263
+22,392
| +5% | +$5.31M | 0.03% | 458 |
|
|
2022
Q3 | $105M | Buy |
425,871
+12,024
| +3% | +$3.66M | 0.04% | 427 |
|
|
2022
Q2 | $125M | Buy |
413,847
+11,896
| +3% | +$3.87M | 0.04% | 368 |
|
|
2022
Q1 | $165M | Buy |
401,951
+1,945
| +0.5% | +$761K | 0.05% | 341 |
|
|
2021
Q4 | $188M | Buy |
400,006
+15,549
| +4% | +$6.69M | 0.06% | 316 |
|
|
2021
Q3 | $163M | Sell |
384,457
-333
| -0.1% | -$140K | 0.05% | 331 |
|
|
2021
Q2 | $138M | Sell |
384,790
-2,853
| -0.7% | -$943K | 0.05% | 375 |
|
|
2021
Q1 | $109M | Sell |
387,643
-1,257
| -0.3% | -$360K | 0.04% | 407 |
|
|
2020
Q4 | $110M | Sell |
388,900
-43,529
| -10% | -$12.2M | 0.04% | 376 |
|
|
2020
Q3 | $119M | Sell |
432,429
-165,089
| -28% | -$43.7M | 0.05% | 310 |
|
|
2020
Q2 | $136M | Buy |
597,518
+149,418
| +33% | +$29.4M | 0.07% | 262 |
|
|
2020
Q1 | $68.2M | Buy |
448,100
+18,716
| +4% | +$2.88M | 0.04% | 410 |
|
|
2019
Q4 | $64.5M | Buy |
429,384
+13,795
| +3% | +$2.01M | 0.03% | 497 |
|
|
2019
Q3 | $58.9M | Buy |
415,589
+14,936
| +4% | +$2.06M | 0.03% | 492 |
|
|
2019
Q2 | $50.1M | Buy |
400,653
+68
| +0% | +$8.03K | 0.03% | 563 |
|
|
2019
Q1 | $44.1M | Buy |
400,585
+29,679
| +8% | +$3.09M | 0.03% | 607 |
|
|
2018
Q4 | $36.4M | Buy |
370,906
+7,631
| +2% | +$828K | 0.03% | 596 |
|
|
2018
Q3 | $44.9M | Buy |
363,275
+17,642
| +5% | +$1.98M | 0.03% | 589 |
|
|
2018
Q2 | $34.3M | Buy |
345,633
+23,700
| +7% | +$2.18M | 0.03% | 697 |
|
|
2018
Q1 | $28.4M | Buy |
321,933
+18,960
| +6% | +$1.77M | 0.02% | 779 |
|
|
2017
Q4 | $29.9M | Buy |
302,973
+12,352
| +4% | +$1.21M | 0.02% | 707 |
|
|
2017
Q3 | $28M | Buy |
290,621
+22,237
| +8% | +$2.01M | 0.02% | 681 |
|
|
2017
Q2 | $25.4M | Buy |
268,384
+20,325
| +8% | +$1.87M | 0.02% | 694 |
|
|
2017
Q1 | $20.2M | Buy |
248,059
+15,621
| +7% | +$1.31M | 0.02% | 827 |
|
|
2016
Q4 | $19.7M | Buy |
232,438
+10,535
| +5% | +$828K | 0.02% | 768 |
|
|
2016
Q3 | $16.5M | Buy |
221,903
+18,411
| +9% | +$1.46M | 0.02% | 810 |
|
|
2016
Q2 | $15.4M | Sell |
203,492
-106,266
| -34% | -$7.73M | 0.02% | 794 |
|
|
2016
Q1 | $21.5M | Buy |
309,758
+7,335
| +2% | +$441K | 0.03% | 581 |
|
|
2015
Q4 | $18.2M | Buy |
302,423
+19,121
| +7% | +$1.15M | 0.02% | 646 |
|
|
2015
Q3 | $15.3M | Buy |
283,302
+9,731
| +4% | +$567K | 0.02% | 689 |
|
|
2015
Q2 | $15.9M | Buy |
273,571
+10,149
| +4% | +$566K | 0.02% | 689 |
|
|
2015
Q1 | $15.9M | Buy |
263,422
+19,540
| +8% | +$1.04M | 0.02% | 689 |
|
|
2014
Q4 | $13M | Buy |
243,882
+37
| +0% | +$1.85K | 0.02% | 728 |
|
|
2014
Q3 | $10.9M | Buy |
243,845
+7,786
| +3% | +$331K | 0.02% | 754 |
|
|
2014
Q2 | $9.96M | Sell |
236,059
-24,540
| -9% | -$1.05M | 0.02% | 846 |
|
|
2014
Q1 | $11.5M | Buy |
260,599
+42,136
| +19% | +$1.98M | 0.02% | 702 |
|
|
2013
Q4 | $10.7M | Buy |
218,463
+10,123
| +5% | +$474K | 0.02% | 674 |
|
|
2013
Q3 | $8.63M | Buy |
208,340
+6,464
| +3% | +$247K | 0.02% | 733 |
|
|
2013
Q2 | $7.22M | Buy |
+201,876
| New | +$6.64M | 0.02% | 759 |
|
Other funds holding WST
GIM
Charles Schwab's WST Position: Q2 2026 in Review
Charles Schwab increased its West Pharmaceutical (WST) stake by 5.3% in Q2 2026, buying an estimated $9.07M and bringing the position to 583,984 shares worth $210M. The position accounts for 0.03% of the portfolio, ranked #443.
Charles Schwab first reported a position in WST in Q2 2013 and has held it in 53 quarters since. 829 funds tracked by Wall St. Rank hold WST as of Q2 2026.
- Charles Schwab held 583,984 shares of West Pharmaceutical worth $210M as of Q2 2026.
- Charles Schwab bought 29,652 West Pharmaceutical shares in Q2 2026, an estimated $9.07M.
- West Pharmaceutical made up 0.03% of Charles Schwab's portfolio in Q2 2026, its #443 holding.
- Charles Schwab first reported a position in West Pharmaceutical in Q2 2013 and has held it in 53 quarters since.
- 829 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.